{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-008887","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.966138+00:00","generated_at":"2026-06-27T05:34:06.852266+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"InMed board director Catherine Sazdanoff resigns; Janet Grove appointed as replacement","bullets":["Catherine Sazdanoff resigned from Board effective Feb 11, 2022 due to personal reasons.","Janet Grove appointed as director effective Feb 11, 2022 to fill vacancy; term expires at 2022 AGM.","Grove to serve on Compensation and Nominating & Governance Committees.","Grove receives $35K annual retainer, up to $15K for committee service, plus stock options for 14,000 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-008887","json":"https://secwatch.observer/filing/0001213900-22-008887.json","markdown":"https://secwatch.observer/filing/0001213900-22-008887.md","text":"https://secwatch.observer/filing/0001213900-22-008887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/ea156089-8k_inmedpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:34:06.852266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1083291172","claim":"Catherine Sazdanoff resigned as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On February 11, 2022, Catherine Sazdanoff resigned from the Board of Directors (the “Board”) (including from the Compensation Committee, the Nominating & Governance Committee and the Audit Committee) of InMed Pharmaceuticals Inc. (the “Company”), effective as of February 11,2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ea0eeba70a","claim":"Janet Grove was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On February 11, 2022, the Board appointed Janet Grove as a director of the Board to fill the vacancy created by Ms. Sazdanoff’s resignation, effective as of February 11, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}